<DOC>
	<DOCNO>NCT00035022</DOCNO>
	<brief_summary>The purpose study determine intravenous BCX-1777 give safely improve relapsed refractory aggressive T-cell leukemia lymphoma .</brief_summary>
	<brief_title>Study Intravenous BCX-1777 Relapsed Refractory Aggressive T-Cell Leukemias Lymphomas</brief_title>
	<detailed_description>Despite great stride make improve outcome frontline program intensive chemotherapy patient aggressive T-cell malignancy , prognosis relapse refractory T-cell leukemia lymphoma poor . BCX-1777 purine nucleoside phosphorylase ( PNP ) inhibitor potential T-cell target therapy . The purpose phase I portion study determine maximum tolerate dose ( MTD ) BCX-1777 dose study phase II portion study . The purpose phase II portion study determine safety efficacy BCX-1777 patient relapse refractory aggressive T-cell malignancy . Patients respond BCX-1777 stable disease may eligible receive additional course treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Previously treat , relapse refractory aggressive Tcell malignancy ( leukemias lymphoma ) histologically prove measurable disease . Capable limited selfcare , confine bed chair 50 % waking hour . All age eligible . Pediatric patient ( &lt; 15 year age ) eligible treat dose level previously test adult . Adequate liver renal function . Patients prior history stem cell transplant meet eligibility requirement . Negative pregnancy test within 72 hour study treatment female childbearing potential . Life expectancy least 2 month . Exclusion : Active serious infection control oral intravenous antibiotic . Treatment investigational antileukemic agent chemotherapy agent last 7 day study entry , unless full recovery sideeffects occur patient rapidly progressive disease judge lifethreatening investigator . Concurrent treatment anticancer agent . Known CNS leukemia lymphoma require intrathecal craniospinal radiation therapy . Lumbar puncture require asymptomatic patient . Pregnant and/or lactate woman ; fertile men woman willing use contraception .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Leukemia , Lymphoma , T-Cell</keyword>
</DOC>